三力制药：拟受让海南大学HXW2324化合物及相关专利 其用于开发阿尔茨海默病新型治疗药物的临床前候选化合物

Core Viewpoint - Sanli Pharmaceutical has signed a technology transfer contract with Hainan University to enhance the commercialization of innovative drug research results, specifically focusing on the development of a new treatment for Alzheimer's disease [1] Group 1: Contract Details - The contract involves the transfer of patent application rights for the HXW2324 compound from Hainan University to Sanli Pharmaceutical [1] - The total transfer price is set at 200 million yuan, which includes a milestone payment of 20 million yuan and a sales commission of 180 million yuan [1] Group 2: Product Focus - The HXW2324 compound is a preclinical candidate aimed at developing a novel treatment for Alzheimer's disease [1]